CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of kidney and bladder cancer.
  
  LEARNING OBJECTIVES

  • Evaluate recently presented data with adjuvant anti-PD-1 antibody therapy for patients with renal cell carcinoma (RCC) at high risk for recurrence after nephrectomy, and consider the potential clinical role of this treatment strategy.
  • Effectively apply research findings and other clinical and biologic factors in the best-practice selection of first-line therapy for patients with metastatic RCC.
  • Develop a rational approach to the sequencing of systemic therapies for patients with advanced RCC who experience disease progression on first-line treatment, incorporating multikinase inhibitors, mTOR inhibitors, immunotherapeutic agents and others.
  • Consider available data supporting the use of anti-PD-1 antibody therapy for high-risk non-muscle-invasive bladder cancer that is unresponsive to BCG, and determine how this strategy can be appropriately integrated into current care.
  • Assess the recent FDA approval of adjuvant anti-PD-1 antibody therapy for patients with high-risk muscle-invasive bladder cancer, and consider the current clinical role of this strategy.
  • Review available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed metastatic urothelial bladder carcinoma (UBC), and determine the current utility of these agents in clinical practice.
  • Recall pivotal clinical trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with these approaches would be appropriate.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with common and emerging systemic therapies for RCC and UBC.
  • Reflect on available and emerging data with investigational agents and strategies currently in testing for RCC and UBC, and appropriately refer patients for clinical trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Elizabeth R Plimack, MD, MS
  Chief, Division of Genitourinary Medical Oncology
  Director, Genitourinary Clinical Research
  Professor, Department of Hematology/Oncology
  Fox Chase Cancer Center
  Temple Health
  Philadelphia, Pennsylvania
  
  Advisory Committee: Astellas, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Genentech, a member of the Roche Group, Janssen Biotech Inc, MEI Pharma Inc, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Contracted Research: Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Infinity Pharmaceuticals Inc.
  
  Thomas Powles, MBBS, MRCP, MD
  Professor of Genitourinary Oncology
  Barts Cancer Institute
  Director of Barts Cancer Centre
  Queen Mary University of London
  London, United Kingdom
  
  Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Travel/Accommodation/Expenses: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme Corp, Pfizer Inc, Roche Laboratories Inc. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas and Seagen Inc, Eisai Inc, Exelixis Inc, and Merck.
  
  Release date: March 2022
  Expiration date: March 2023